These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 32495160)
1. Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance. Lorusso D; García-Donas J; Sehouli J; Joly F Target Oncol; 2020 Jun; 15(3):391-406. PubMed ID: 32495160 [TBL] [Abstract][Full Text] [Related]
2. Real-World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10. Drew Y; Kristeleit RS; Oaknin A; Ray-Coquard I; Haris NM; Swisher EM Oncologist; 2020 Jan; 25(1):e109-e119. PubMed ID: 31575788 [TBL] [Abstract][Full Text] [Related]
3. Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. Labadie BW; Morris DS; Bryce AH; Given R; Zhang J; Abida W; Chowdhury S; Patnaik A Cancer Manag Res; 2022; 14():673-686. PubMed ID: 35210863 [TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, Kristeleit RS; Oaknin A; Ray-Coquard I; Leary A; Balmaña J; Drew Y; Oza AM; Shapira-Frommer R; Domchek SM; Cameron T; Maloney L; Goble S; Lorusso D; Ledermann JA; McNeish IA Int J Gynecol Cancer; 2019 Nov; 29(9):1396-1404. PubMed ID: 31685558 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of rucaparib in patients with recurrent high-grade ovarian carcinoma: A systematic review and meta-analysis. Adrianto N; Mangkuliguna G; Tandiono EJ; Sibarani CNR Taiwan J Obstet Gynecol; 2024 Sep; 63(5):601-609. PubMed ID: 39266137 [TBL] [Abstract][Full Text] [Related]
7. Rucaparib: a novel PARP inhibitor for Colombo I; Lheureux S; Oza AM Drug Des Devel Ther; 2018; 12():605-617. PubMed ID: 29606854 [TBL] [Abstract][Full Text] [Related]
8. Rucaparib: A Poly(ADP-Ribose) Polymerase Inhibitor for BRCA-Mutated Relapsed Ovarian Cancer. Moore DC; Ringley JT; Patel J J Pharm Pract; 2019 Apr; 32(2):219-224. PubMed ID: 29166829 [TBL] [Abstract][Full Text] [Related]
9. Rucaparib: A Review in Ovarian Cancer. Shirley M Target Oncol; 2019 Apr; 14(2):237-246. PubMed ID: 30830551 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10. Kristeleit RS; Drew Y; Oza AM; Domchek SM; Banerjee S; Glasspool RM; Balmaña J; Chen LM; Patel MR; Burris HA; Safra T; Borrow J; Lin KK; Goble S; Maloney L; Shapira-Frommer R Br J Cancer; 2023 Jan; 128(2):255-265. PubMed ID: 36482193 [TBL] [Abstract][Full Text] [Related]
11. A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline Kristeleit R; Shapiro GI; Burris HA; Oza AM; LoRusso P; Patel MR; Domchek SM; Balmaña J; Drew Y; Chen LM; Safra T; Montes A; Giordano H; Maloney L; Goble S; Isaacson J; Xiao J; Borrow J; Rolfe L; Shapira-Frommer R Clin Cancer Res; 2017 Aug; 23(15):4095-4106. PubMed ID: 28264872 [No Abstract] [Full Text] [Related]
12. How safe is rucaparib in ovarian cancer? Cosgrove CM; O'Malley DM Expert Opin Drug Saf; 2018 Dec; 17(12):1249-1255. PubMed ID: 30449210 [No Abstract] [Full Text] [Related]
13. Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment. Grechko N; Skarbova V; Tomaszewska-Kiecana M; Ramlau R; Centkowski P; Drew Y; Dziadziuszko R; Zemanova M; Beltman J; Nash E; Habeck J; Liao M; Xiao J Cancer Chemother Pharmacol; 2021 Aug; 88(2):259-270. PubMed ID: 33909097 [TBL] [Abstract][Full Text] [Related]
14. Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease. Dal Molin GZ; Westin SN; Coleman RL Future Oncol; 2018 Dec; 14(30):3101-3110. PubMed ID: 30105925 [TBL] [Abstract][Full Text] [Related]
15. ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer. Monk BJ; Coleman RL; Fujiwara K; Wilson MK; Oza AM; Oaknin A; O'Malley DM; Lorusso D; Westin SN; Safra T; Herzog TJ; Marmé F; N Eskander R; Lin KK; Shih D; Goble S; Grechko N; Hume S; Maloney L; McNeish IA; Kristeleit RS Int J Gynecol Cancer; 2021 Dec; 31(12):1589-1594. PubMed ID: 34593565 [TBL] [Abstract][Full Text] [Related]
16. Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial. Kristeleit R; Lisyanskaya A; Fedenko A; Dvorkin M; de Melo AC; Shparyk Y; Rakhmatullina I; Bondarenko I; Colombo N; Svintsitskiy V; Biela L; Nechaeva M; Lorusso D; Scambia G; Cibula D; Póka R; Oaknin A; Safra T; Mackowiak-Matejczyk B; Ma L; Thomas D; Lin KK; McLachlan K; Goble S; Oza AM Lancet Oncol; 2022 Apr; 23(4):465-478. PubMed ID: 35298906 [TBL] [Abstract][Full Text] [Related]
17. Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer. Musella A; Bardhi E; Marchetti C; Vertechy L; Santangelo G; Sassu C; Tomao F; Rech F; D'Amelio R; Monti M; Palaia I; Muzii L; Benedetti Panici P Cancer Treat Rev; 2018 May; 66():7-14. PubMed ID: 29605737 [TBL] [Abstract][Full Text] [Related]
18. Rucabarib: A new lease of life for ovarian cancer patients. Sachdeva S; Rabbani TK J Cancer Res Ther; 2021; 17(4):1123-1124. PubMed ID: 34528576 [TBL] [Abstract][Full Text] [Related]
19. The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma. Colombo N; Oza AM; Lorusso D; Aghajanian C; Oaknin A; Dean A; Weberpals JI; Clamp AR; Scambia G; Leary A; Holloway RW; Gancedo MA; Fong PC; Goh JC; O'Malley DM; Armstrong DK; Banerjee S; García-Donas J; Swisher EM; Meunier J; Cameron T; Maloney L; Goble S; Bedel J; Ledermann JA; Coleman RL Gynecol Oncol; 2020 Oct; 159(1):101-111. PubMed ID: 32861537 [TBL] [Abstract][Full Text] [Related]
20. Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting. Tookman L; Krell J; Nkolobe B; Burley L; McNeish IA Ther Adv Med Oncol; 2020; 12():1758835920921980. PubMed ID: 32523631 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]